Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03PQW
|
||||
| Former ID |
DNCL002439
|
||||
| Drug Name |
BAY 79-4620
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] | Phase 1 | [1] | ||
| Company |
Bayer HealthCare Pharmaceuticals
|
||||
| Target and Pathway | |||||
| Target(s) | Carbonic anhydrase IX | Target Info | [2] | ||
| KEGG Pathway | Nitrogen metabolism | ||||
| Pathway Interaction Database | HIF-1-alpha transcription factor network | ||||
| Reactome | Regulation of gene expression by Hypoxia-inducible Factor | ||||
| Reversible hydration of carbon dioxide | |||||
| WikiPathways | Vitamin D Receptor Pathway | ||||
| Reversible Hydration of Carbon Dioxide | |||||
| Regulation of Hypoxia-inducible Factor (HIF) by Oxygen | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01028755) To Determine Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health. | ||||
| REF 2 | Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9. Mol Cancer Ther. 2012 Feb;11(2):340-9. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.